Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 5/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | DDO | Q99489 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30434363 | 0.81 | MAPK1 (0.61) | KDM4EALDH1A1HPGDMAPK1NPSR1 | |
| SCHEMBL5678790 | 0.81 | MAPK1 (0.61) | KDM4EALDH1A1HPGDMAPK1NPSR1 | |
| SCHEMBL30730349 | 0.80 | NLRP3 (0.60) | KDM4EALDH1A1HPGDMAPK1GAA | |
| SCHEMBL5498288 | 0.80 | NLRP3 (0.60) | KDM4EALDH1A1HPGDMAPK1GAA | |
| SCHEMBL8306652 | 0.79 | KDM4E (0.59) | KDM4EALDH1A1HPGDMAPK1GAA | |
| SCHEMBL28431176 | 0.77 | BRD4 (0.53) | KDM4EALDH1A1HPGDMAPK1NPSR1 | |
| SCHEMBL6402311 | 0.76 | DAO (0.59) | KDM4EALDH1A1HPGDMAPK1NPSR1 | |
| SCHEMBL17618004 | 0.76 | KDM4E (0.58) | KDM4EALDH1A1HPGDMAPK1GAA | |
| SCHEMBL5473260 | 0.75 | KDM4E (0.58) | KDM4EALDH1A1HPGDMAPK1GAA | |
| Bicarbonate SCHEMBL6993932 | 0.75 | MAPK1 (0.61) | KDM4EALDH1A1HPGDMAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-08-29 | — | — | US | disclosed |
| WO-2023278222-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL1RN | KDM4E 878/4885ALDH1A1 648/4885HPGD 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.